Top-Rated StocksTop-RatedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free RARE Stock Alerts $42.75 -0.45 (-1.04%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$42.68▼$46.0150-Day Range$42.31▼$53.6952-Week Range$31.52▼$54.98Volume1.14 million shsAverage Volume786,481 shsMarket Capitalization$3.55 billionP/E RatioN/ADividend YieldN/APrice Target$88.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Ultragenyx Pharmaceutical alerts: Email Address Ultragenyx Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside105.8% Upside$88.00 Price TargetShort InterestBearish5.27% of Shares Sold ShortDividend StrengthN/ASustainability-2.28Upright™ Environmental ScoreNews Sentiment-0.19Based on 22 Articles This WeekInsider TradingSelling Shares$1.65 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.38) to ($5.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector137th out of 904 stocksPharmaceutical Preparations Industry48th out of 423 stocks 4.5 Analyst's Opinion Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.27% of the outstanding shares of Ultragenyx Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently increased by 11.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUltragenyx Pharmaceutical has received a 49.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Triheptanoin", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Ultragenyx Pharmaceutical is -2.28. Previous Next 1.6 News and Social Media Coverage News SentimentUltragenyx Pharmaceutical has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Ultragenyx Pharmaceutical this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for RARE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,645,983.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.38) to ($5.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -5.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUltragenyx Pharmaceutical has a P/B Ratio of 12.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Read More RARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RARE Stock News HeadlinesMay 5, 2024 | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $47.00May 4, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter ResultsMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.May 4, 2024 | insidermonkey.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call TranscriptMay 4, 2024 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by AnalystsMay 4, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)May 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)May 3, 2024 | markets.businessinsider.comWedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)May 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.May 3, 2024 | finance.yahoo.comUltragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...May 2, 2024 | sfgate.comUltragenyx: Q1 Earnings SnapshotMay 2, 2024 | msn.comUltragenyx Pharmaceutical GAAP EPS of -$2.03 misses by $0.28, revenue of $108.8M misses by $7.64MMay 2, 2024 | investorplace.comRARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024May 2, 2024 | globenewswire.comUltragenyx Reports First Quarter 2024 Financial Results and Corporate UpdateApril 30, 2024 | globenewswire.comUltragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare DiseaseApril 30, 2024 | markets.businessinsider.comUltragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline PotentialApril 30, 2024 | finance.yahoo.comUltragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)April 26, 2024 | americanbankingnews.comTD Cowen Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $61.00April 25, 2024 | globenewswire.comUltragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate UpdateApril 24, 2024 | nasdaq.comFirst Week of RARE June 21st Options TradingApril 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Ultragenyx Pharmaceutical (RARE)April 22, 2024 | markets.businessinsider.comForecasting The Future: 11 Analyst Projections For Ultragenyx PharmaceuticalApril 19, 2024 | globenewswire.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)April 15, 2024 | msn.comWhy Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionApril 15, 2024 | markets.businessinsider.comUltragenyx Reports Positive Interim Phase 1/2 Data With GTX-102 - Quick FactsApril 15, 2024 | finance.yahoo.comUltragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102See More Headlines Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/05/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RARE CUSIPN/A CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,276Year Founded2010Price Target and Rating Average Stock Price Target$88.00 High Stock Price Target$133.00 Low Stock Price Target$47.00 Potential Upside/Downside+105.8%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($8.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-606,640,000.00 Net Margins-138.58% Pretax Margin-140.12% Return on Equity-421.88% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.49 Sales & Book Value Annual Sales$434.25 million Price / Sales8.18 Cash FlowN/A Price / Cash FlowN/A Book Value$3.35 per share Price / Book12.76Miscellaneous Outstanding Shares83,090,000Free Float77,444,000Market Cap$3.55 billion OptionableOptionable Beta0.68 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Emil D. Kakkis M.D. (Age 64)Ph.D., Founder, President, CEO & Director Comp: $1.37MMr. John Richard Pinion II (Age 58)Chief Quality Operations Officer & Executive VP of Translational Sciences Comp: $806.19kMr. Erik Harris (Age 53)Executive VP & Chief Commercial Officer Comp: $848.24kMr. Howard Horn (Age 46)Executive VP of Corporate Strategy & CFO Mr. Theodore A. Huizenga (Age 53)Senior VP, Corporate Controller & Principal Accounting Officer Ms. Danielle KeatleySenior Director of Investor Relations & Corporate CommunicationsMs. Karah Herdman Parschauer J.D. (Age 46)Chief Legal Officer & Executive VP of Corporate Affairs Comp: $595.01kMr. Ernie W. Meyer (Age 59)Chief Human Resources Officer & Executive VP Mr. Thomas R. Kassberg (Age 64)Chief Business Officer & Executive VP Comp: $714.84kMr. Vimal Srivastava (Age 59)Senior Vice President of Business Development & Alliance Management More ExecutivesKey CompetitorsCrinetics PharmaceuticalsNASDAQ:CRNXPrestige Consumer HealthcareNYSE:PBHBiohavenNYSE:BHVNInsmedNASDAQ:INSMCymaBay TherapeuticsNASDAQ:CBAYView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 10,549 shares on 5/3/2024Ownership: 0.013%Nordea Investment Management ABSold 422 shares on 5/2/2024Ownership: 0.054%Mirae Asset Global Investments Co. Ltd.Bought 122,412 shares on 5/1/2024Ownership: 0.278%BNP Paribas Financial MarketsSold 137,388 shares on 5/1/2024Ownership: 0.024%Capstone Investment Advisors LLCBought 4,863 shares on 5/1/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions RARE Stock Analysis - Frequently Asked Questions Should I buy or sell Ultragenyx Pharmaceutical stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RARE shares. View RARE analyst ratings or view top-rated stocks. What is Ultragenyx Pharmaceutical's stock price target for 2024? 12 brokers have issued 1-year target prices for Ultragenyx Pharmaceutical's stock. Their RARE share price targets range from $47.00 to $133.00. On average, they predict the company's stock price to reach $88.00 in the next twelve months. This suggests a possible upside of 105.8% from the stock's current price. View analysts price targets for RARE or view top-rated stocks among Wall Street analysts. How have RARE shares performed in 2024? Ultragenyx Pharmaceutical's stock was trading at $47.82 on January 1st, 2024. Since then, RARE shares have decreased by 10.6% and is now trading at $42.75. View the best growth stocks for 2024 here. When is Ultragenyx Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our RARE earnings forecast. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.31. The biopharmaceutical company earned $108.83 million during the quarter, compared to analyst estimates of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative trailing twelve-month return on equity of 421.88%. The company's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.33) EPS. What ETFs hold Ultragenyx Pharmaceutical's stock? ETFs with the largest weight of Ultragenyx Pharmaceutical (NASDAQ:RARE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Tema Cardiovascular and Metabolics ETF (HRTS), Motley Fool Mid-Cap Growth ETF (TMFM), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA) and Simplify Health Care ETF (PINK). What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.0 million-$530.0 million, compared to the consensus revenue estimate of $513.0 million. What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO? 41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM). Who are Ultragenyx Pharmaceutical's major shareholders? Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Mirae Asset Global Investments Co. Ltd. (0.28%), Privium Fund Management B.V. (0.26%), WCM Investment Management LLC (0.19%), Assenagon Asset Management S.A. (0.17%), Hennion & Walsh Asset Management Inc. (0.06%) and Nordea Investment Management AB (0.05%). Insiders that own company stock include Camille L Bedrosian, Corazon (Corsee) D Sanders, Dennis Karl Huang, Emil D Kakkis, Eric Crombez, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Theodore Alan Huizenga and Thomas Richard Kassberg. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RARE) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.